secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020572
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M
---------------------------------------------------------------------------

- Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.
- Advanced Wound Care revenue $100.9M (+12% YoY); Surgical & Sports Medicine $6.7M (-4% YoY).
- Adjusted EBITDA $3.8M vs $5.0M prior year; adjusted net loss $0.7M.
- FY2023 guidance raised: revenue $454-466M, net income $3-11M, adjusted EBITDA $38-49M.
- Cash $88.7M, debt $69.9M at March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/0000950170-23-020572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/orgo-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer